Alnylam Pharmaceuticals secures FDA clearance for vutrisiran, marking a significant milestone in RNA interference therapeutics for a rare …
Alnylam Pharmaceuticals secures FDA clearance for vutrisiran, marking a significant milestone in RNA interference therapeutics for a rare …
Novartis receives a landmark approval for iptacopan (Fabhalta®), offering new hope for patients with a rare kidney disorder.
Precision BioSciences receives IND clearance to launch US-based trial of PBGENE-HBV, a meganuclease gene-editing candidate for a functional …
Positive safety and efficacy review by independent board positions MaaT013 as Europe’s potential first-approved microbiome-based drug for severe …
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
Promising clinical results highlight Gilead’s innovative approach to long-acting HIV treatment, aiming to improve patient adherence and outcomes.
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Major pharma players unveil significant clinical trial progress and strategic collaborations targeting obesity and cardiovascular health.
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
Already a subscriber? Log in